

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-14. (Canceled).

15. (New) A method of screening compounds to identify a candidate compound for inhibiting the binding of CD11b/CD18 to a selected ligand of CD11b/CD18, the method comprising:

- (a) measuring the binding of a substantially pure polypeptide comprising amino acids 128-320 of SEQ ID NO:43 to the selected ligand in the presence of a test compound;
- (b) measuring the binding of the substantially pure polypeptide comprising amino acids 128-320 of SEQ ID NO:43 to the selected ligand in the absence of the test compound;
- (c) identifying the compound as a candidate compound for inhibiting the binding of CD11b/CD18 to a selected ligand of CD11b/CD18 if the binding measured in step (a) is less than the binding measured in step (b).

16. (New) The method of claim 15 wherein the substantially pure polypeptide consists essentially of a polypeptide fragment of human CD11b.

17. (New) The method of claim 15 wherein the polypeptide is detectably labeled.

18. (New) A method of screening compounds to identify a candidate compound for inhibiting the binding of CD11b/CD18 to a selected ligand of CD11b/CD18, the method comprising:

- (a) measuring the binding of a recombinant polypeptide comprising amino acids 128-320 of SEQ ID NO:43 to the selected ligand in the presence of a test compound;
- (b) measuring the binding of the recombinant polypeptide comprising amino acids 128-320 of SEQ ID NO:43 to the selected ligand in the absence of the test compound;
- (c) identifying the compound as a candidate compound for inhibiting the binding of CD11b/CD18 to a selected ligand of CD11b/CD18 if the binding measured in step (a) is less than the binding measured in step (b).

19. (New) The method of claim 18 wherein the recombinant polypeptide consists essentially of a polypeptide fragment of human CD11b.

20. (New) The method of claim 18 wherein the recombinant polypeptide is detectably labeled.

21. (New) A method of screening compounds to identify a candidate compound for inhibiting the binding of CD11b/CD18 to a selected ligand of CD11b/CD18, the method comprising:

- (a) measuring the binding of a substantially pure polypeptide fragment of human CD11b comprising amino acids 128-320 of SEQ ID NO:43 to the selected ligand in the presence of a test compound;
- (b) measuring the binding of the substantially pure polypeptide fragment of human CD11b comprising amino acids 128-320 of SEQ ID NO:43 to the selected ligand in the absence of the test compound;
- (c) identifying the compound as a candidate compound for inhibiting the binding of CD11b/CD18 to a selected ligand of CD11b/CD18 if the binding measured in step (a) is less than the binding measured in step (b).

Applicant : M. Amin Arnaout
Serial No. :
Filed : Herewith
Page : 5 of 6

Attorney's Docket No.: 00786-267003

22. (New) The method of claim 21 wherein the substantially pure CD11b polypeptide is detectably labeled.